A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 1)
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Delgocitinib (Primary)
- Indications Eczema
- Focus Registrational; Therapeutic Use
- Acronyms DELTA 1
- Sponsors LEO Pharma
- 25 Jul 2024 Results from DELTA 1 and DELTA 2 trials published in The Lancet.
- 19 Jul 2024 According to a LEO Pharma media release, company announced publication of data from DELTA 1 and DELTA 2 trials in The Lancet.
- 12 Jan 2024 According to a LEO Pharma media release, the company will present safety and efficacy result from this study and pooled data from the DELTA 1 and DELTA 2 at the upcoming Winter Clinical and Maui Derm conferences this month. The 2024 Winter Clinical Conference will take place Jan. 12-17 in Honolulu, Hawaii, while Maui Derm is being held from Jan. 22-26 in Maui, Hawaii.